Navigation Links
Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
Date:10/23/2008

ka provides us with a tremendous strategic advantage in developing novel drugs for heart failure," said James S. Kuo, M.D., M.B.A., Duska's Chairman and CEO.

About Heart Failure

Heart failure, a condition characterized by the inability of the heart to effectively pump blood as well as by fluid accumulation in the lungs and other tissues, is suffered by an estimated five million Americans and is responsible for 300,000 deaths in the U.S. annually, according to the National Heart, Lung and Blood Institute. It is the single largest Medicare expense, at a cost of $33.2 billion each year. The five-year mortality rate with heart failure can be as high as 50 percent.

About Duska Therapeutics

Duska Therapeutics, Inc. (Duska) is a specialty pharmaceutical company that develops new cardiovascular medicines based upon the emerging new pharmacology of adenosine triphosphate (ATP) and nitric oxide (NO). These two molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which by several pharmaceuticals constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Duska is developing a portfolio of investigational medicines, two of which are in late stages of clinical testing. Duska's ATPace is expected to enter a pivotal Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia. Duska's CDP-1050 is expected to commence a Phase 2 clinical trial for the treatment of heart failure. In addition, Duska has a preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For more information, visit http://www.duskatherapeutics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado
2. CORD:USE Cord Blood Bank is Proud to Announce that Cord Blood Pioneer and Leading Transplanter Dr. Eliane Gluckman has Joined its Team
3. ThalesNano, Inc. Forms Collaborations with Leading US Universities based on the Award Winning H-Cube(R) and H-Cube Midi(TM)
4. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
5. Arius announces leading independent proxy firm, RiskMetrics ISS Canada, recommends shareholders vote for the arrangement involving its acquisition by Roche
6. Brain Cancer Patients at Two Leading Hospitals Treated Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems
7. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
8. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
9. iZumi Bio, Inc. Recruits Leading iPS Scientist, John Dimos, to Translate Stem Cell Breakthrough Into Patient Benefits
10. Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV
11. Leading Lobbying Firm Celebrates Growth and New Name: Troutman Sanders Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative veterinary ... of its canine osteoarthritis stem cell product, currently under development for FDA approval. ... will be marketed in the US by Aratana. This product, termed AT-016, is ...
(Date:7/30/2015)... 30, 2015 HIGHLIGHTS:Q2 2015 Results ... , Reported sales were $697 million compared to ... grew organically by 8%, and changes in foreign currency ... sales by 1%. , By business unit, organic ... and 11% in SAFC Commercial. , Reported diluted ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... publie ses résultats pour le premier semestre 2015. ... les résultats. Visionner l,interview vidéo et ... Au sommaire de l,interview :  ... Moteurs de croissance - Diabète ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... Leonhardt,s Launchpads ( www.leonhardtslaunchpads.com ), at the ... Center ( www.uncm.edu/STIC.php ), 2330 Circadian Way, Santa ... Grand Opening on Tuesday, November 9th from 3pm ... incubator for startup businesses and high-potential entrepreneurs in ...
... Inc. Prices $50 Million Public Offering ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... Davis Phinney Foundation ( http://www.davisphinneyfoundation.org ), a non-profit foundation ... help people to live well with Parkinson,s disease, today ... Exercise and Parkinson,s: Questions and Answers from the Experts ... experts in the fields of physical therapy and exercise ...
Cached Biology Technology:OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 2OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 3OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 4OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 5OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 6OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 7OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 8OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering 9Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 2Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 3Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinson's Disease 4
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... of Soil, they're just clever Lab guys. A team from ... Science Magazine with a new way to count bugs in ... our feet. , "Computational Improvements Reveal Great Bacterial Diversity and ... and John Dunbar, of Los Alamos' Bioscience Division, describes a ...
... CropScience and DuPont have developed two new classes of ... more effective way to fight pest insects that damage ... compounds designed to activate a novel insecticide target called ... problem of insecticide resistance, the researchers say. They described ...
... at The Schepens Eye Research Institute have discovered that ... in the eye and other parts of the body ... body's immune response and protect delicate tissues that cannot ... believe that this discovery may ultimately help in the ...
Cached Biology News:Using computers and DNA to count bacteria 2Novel compounds show promise as safer, more potent insecticides 2A protein in the eye may prevent immune response and protect eyes from disease 2
... LV Series offers high performance miniature stepper ... 23, and 34 frame sizes. These space-efficient ... life science applications, including medical instrumentation, medical ... automation systems., Meets a wide range ...
... kit for a single fragment based screening project: , ... , 96 shape-diverse mixtures of 4 (5 ... files for structure refinement , Individual compounds ... are at ca. 50 mM. Supplied in 5 96-well trays. ...
... The pTriEx™ vectors combine the proven features ... mammalian systems and provides all of the ... in one vector backbone. The pTriEx vectors ... various target genes in all three expression ...
... the first instrument engineered to match the ... by thousands of research centers worldwide. It ... which are ideally suited for high-speed temperature ... extremely high surface-area-to-volume ratio. ,By combining glass ...
Biology Products: